Form 8-K Filing by Bluejay Diagnostics, Inc.

Bluejay Diagnostics, Inc. filed a Form 8-K on March 13, 2026, to disclose a response letter sent to NorthStrive Fund II LP. This response addresses a letter received from NorthStrive on March 11, 2026, which suggested Bluejay pursue an acquisition of a Phase-1-ready therapeutic program for refractory chronic cough to expand its clinical pipeline. Bluejay's management is currently focused on advancing its Symphony™ platform and critical care biomarker menu, including clinical studies, manufacturing scale-up, and FDA submission. The company will evaluate the acquisition opportunity with advisors to assess its potential synergy with the existing platform and its impact on shareholder value, considering the limited information provided by NorthStrive. They have requested further diligence analysis and direct contact from the potential counterparty if available. The filing also includes Exhibit 99.1, the response letter itself.